The Peptide Field. P21 peptide: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/p21

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=p21#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Animal and cell studies only. No FDA-approved U.S. P21 product was found.

Exact product limits: FDA lists P-21, P021, and P21 under one chemical record. This record does not prove that a sold product contains the same compound used in a study. A name alone does not prove what is in a product or whether it was made safely.

Human outcomes: Unclear. No P021 study in people was found in the searches completed on August 30, 2026.

Body effects in people: Unclear. Studies measured effects in mice, rats, or cells. They do not show what happens in people.

What the evidence shows: A 2010 mouse study reported changes in learning, memory, and the growth of new brain cells. Later mouse studies reported changes in memory, nerve-cell connections, tau, or amyloid. Tau and amyloid are proteins studied in Alzheimer’s disease. An aged-rat study measured lower tau after P021 treatment. A cell study and another mouse study had mixed results. None of these studies tested P21 in people.

What remains unknown: No P021 study in people was found. The reviewed evidence does not show whether it improves memory, prevents dementia, or treats Alzheimer’s disease in people. It also does not establish a safe amount, long-term effects, or the quality of products sold with this name. Tests in human-derived cells happen in a lab. They are not studies in people.

Safety limits: No reviewed study sets a safe amount or way to take P21. Long-term safety in people is also unknown. This guide gives no directions for use, buying advice, or treatment advice.

Approval claim: “A P21 substance record means P21 is FDA-approved.”
Verdict: Misleading. FDA says a Unique Ingredient Identifier, or UNII, helps identify a substance. It does not mean that FDA reviewed or approved a drug. No FDA-approved P21 product was found under the reviewed names.
Evidence basis: Regulatory or product record. Scope: United States drug-approval status as checked for P21, P021, and P-21 on August 30, 2026.
Claim sources: https://precision.fda.gov/uniisearch/srs/unii/VV8CZC8PAS https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA substance record for P-21, P021, and P21. 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/VV8CZC8PAS

PubMed · FEBS Letters. P21 learning, memory, and nerve-cell study in normal mice. 2010. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/20600002/

PubMed · Neurobiology of Disease. Chronic P021 study in an Alzheimer-like mouse model. 2014. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/25046994/

PubMed · Alzheimer’s Research & Therapy. Early P021 study in an Alzheimer-like mouse model. 2017. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/28655344/

PubMed · Journal of Alzheimer’s Disease. P021 tau study in aged rats. 2015. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/26401692/

PubMed · Journal of Neurodevelopmental Disorders. P021 study in lab-grown human nerve cells and a mouse model. 2024. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/39592934/

ClinicalTrials.gov. ClinicalTrials.gov intervention search for P021. 2026. Accessed 2026-08-30. https://clinicaltrials.gov/search?intr=P021

National Center for Biotechnology Information. NCBI Gene record for human CDKN1A, also called p21. 2026. Accessed 2026-08-30. https://www.ncbi.nlm.nih.gov/gene/1026

U.S. Food and Drug Administration. Drugs@FDA approved-drug search. 2026. Accessed 2026-08-30. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Keep the limits, review date, and sources with this record. Check the current source for changes.